|
PFN2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.62723176547297E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.25339746862119E-11 |
| Normal-vs-Stage2 |
1.220460E-04 |
| Normal-vs-Stage3 |
7.17749970569059E-10 |
| Normal-vs-Stage4 |
1.65556457432103E-12 |
| Stage1-vs-Stage2 |
2.820400E-01 |
| Stage1-vs-Stage3 |
3.413400E-01 |
| Stage1-vs-Stage4 |
1.115720E-03 |
| Stage2-vs-Stage3 |
1.422000E-01 |
| Stage2-vs-Stage4 |
1.679230E-03 |
| Stage3-vs-Stage4 |
1.849560E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.85620416207166E-11 |
| Normal-vs-AfricanAmerican |
2.0618999999944E-05 |
| Normal-vs-Asian |
3.5548008980868E-11 |
| Caucasian-vs-AfricanAmerican |
9.914800E-01 |
| Caucasian-vs-Asian |
1.366220E-01 |
| AfricanAmerican-vs-Asian |
3.807000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.72599983989153E-10 |
| Normal-vs-Female |
3.01891844856073E-12 |
| Male-vs-Female |
4.072600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.71094258152971E-12 |
| Normal-vs-Age(41-60Yrs) |
2.8619000502772E-09 |
| Normal-vs-Age(61-80Yrs) |
3.11370040861902E-10 |
| Normal-vs-Age(81-100Yrs) |
7.490000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.163600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.011200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.194800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.420200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.876000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.281400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.219950E-02 |
| Classical-VS-Follicular |
1.689240E-01 |
| Classical-VS-Other |
3.411800E-01 |
| Classical-VS-Normal |
1.94140259424103E-11 |
| Tall-VS-Follicular |
1.678860E-03 |
| Tall-VS-Other |
2.433000E-01 |
| Tall-VS-Normal |
2.09021688846178E-12 |
| Follicular-VS-Other |
6.238200E-01 |
| Follicular-VS-Normal |
5.01010000042434E-07 |
| Other-VS-Normal |
8.826000E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.52720000482043E-09 |
| Normal-vs-N1 |
8.99280649946377E-15 |
| N0-vs-N1 |
1.377160E-04 |
|
|
